The American Cancer Society has named Michelle M. Le Beau, PhD, director of the University of Chicago Medicine Comprehensive Cancer Center, to its board of directors, with a term beginning on Jan. 1, 2019.

Directors are elected for a two-year term. The all-volunteer board is responsible for setting policy, establishing long-term goals, monitoring general operations, and approving the organizational outcomes and allocation of resources.

“I am honored to join the board of the American Cancer Society – a key partner in the global fight against cancer,” said Le Beau. “I look forward to working with ACS leadership on our shared mission of supporting innovative, practice-changing cancer research, preventing cancer, and improving the quality-of-life of those facing cancer.”

In addition to her role as the director of a National Cancer Institute-designated Comprehensive Cancer Center, Le Beau is the Arthur and Marian Edelstein Professor of Medicine and director of the Cancer Cytogenetics Laboratory at the University of Chicago. She is board-certified in clinical cytogenetics by the American Board of Medical Genetics and Genomics. She is also a member of the National Cancer Policy Forum of the National Academy of Medicine.

More : https://www.uchicagomedicine.org/forefront/cancer-articles/2018/december/michelle-m-le-beau-elected-to-the-american-cancer-society-board-of-directors

Originally published in The Forefront